Author Correction: An investigation into the mechanism of nobiletin’s inhibition of papillary thyroid cancer using network pharmacology analysis and experimental pharmacology
Q.-J. Du, Q. Li, R.-H. Zhou, H. Wang, Q. Yan, W.-J. Dang, J.-J. Guo Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Correction to: European Review for Medical and Pharmacological Sciences 2023; 27 (4): 1553-1564. DOI: 10.26355/eurrev_202302_31398-PMID: 36876711-published online on February 15, 2023.
After publication, the authors applied some corrections to the galley proof:
– The order of Table I and II has been inverted.
– The scale bar of Figure 9A has been inserted in the Legend.
There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.
Free PDF Download
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
Q.-J. Du, Q. Li, R.-H. Zhou, H. Wang, Q. Yan, W.-J. Dang, J.-J. Guo
Author Correction: An investigation into the mechanism of nobiletin’s inhibition of papillary thyroid cancer using network pharmacology analysis and experimental pharmacology
Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 7
Pages: 2715-2715
DOI: 10.26355/eurrev_202304_31896